Randomized trial of chemoimmunotherapy in advanced non-oat-cell lung cancer

Tumori. 1982 Dec 31;68(6):527-30.

Abstract

Thirty patients without any prior chemotherapy and histologically proved non-oat-cell advanced lung cancer entered a randomized trial comparing a combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) and the same combination plus intradermic BCG. Twenty-nine patients were evaluable for survival. Mean survival was 11 and 3.5 months for chemotherapy and chemoimmunotherapy group, respectively. The difference was statistically significant (P less than 0.025). A tumor enhancement can be postulated. Skin tests before treatment (PPD, Candida, Varidase) seem to be prognostic for survival.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • BCG Vaccine / administration & dosage*
  • Carcinoma, Squamous Cell / therapy
  • Carmustine / administration & dosage*
  • Clinical Trials as Topic
  • Cyclophosphamide / administration & dosage*
  • Drug Therapy, Combination
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Male
  • Methotrexate / administration & dosage*
  • Middle Aged
  • Neoplasm Staging

Substances

  • BCG Vaccine
  • Cyclophosphamide
  • Carmustine
  • Methotrexate